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CancerEpidermal growth factor (EGF) receptor (EGFR) is the founding member of the ErbB family of growth factor re-
ceptors that modulate a complex network of intracellular signaling pathways controlling growth, proliferation,
differentiation, and motility. Selenoprotein W (SEPW1) is a highly conserved, diet-regulated 9 kDa
thioredoxin-like protein required for normal cell cycle progression. We report here that SEPW1 is required for
EGF-induced EGFR activation and that it functions by suppressing EGFR ubiquitination and receptor degradation.
SEPW1depletion inhibited EGF-dependent cell cycle entry in breast and prostate epithelial cells. In prostate cells,
SEPW1 depletion decreased EGFR auto-phosphorylation, while SEPW1 overexpression increased EGFR auto-
phosphorylation. SEPW1 depletion increased the rate of EGFR degradation, which decreased total and surface
EGFR and suppressed EGF-dependent EGFR endocytosis, EGFR dimer formation, and activation of EGF-
dependent pathways. EGFR ubiquitination was increased in SEPW1-depleted cells — in agreement with the in-
creased rate of EGFR degradation, and suggests that SEPW1 suppresses EGFR ubiquitination. Ubiquitination-
directed lysozomal degradation controls post-translational EGFR expression and is dysregulated inmany cancers.
Thus, suppression of EGFR ubiquitination by SEPW1 may be related to the putative increase in cancer risk asso-
ciated with high selenium intakes. Knowledge of the mechanisms underlying SEPW1's regulation of EGFR
ubiquitination may reveal new opportunities for nutritional cancer prevention or cancer drug development.
Published by Elsevier B.V.1. Introduction
Epidermal growth factor (EGF) is a 53 amino acid polypeptide
growth factor that regulates cell growth, proliferation and differentia-
tion [1,2]. The EGF receptor (EGFR) is a receptor tyrosine kinase of the
ErbB family, so-named because they are homologous with the erythro-
blastic leukemia viral oncogene. Four members of the oncogenic ErbB
family have been identiﬁed: EGFR (ErbB1, HER1), ErbB2 (HER2),
ErbB3 (HER3), and ErbB4 (HER4). EGFR was the ﬁrst growth factor re-
ceptor to be identiﬁed in cancer cells and is considered a human
proto-oncogene. EGFR is expressed in approximately one-third of can-
cers and the EGFR system is constitutively activated in many tumors.
EGFR is activated by binding of various peptide growth factors, includ-
ing EGF, transforming growth factor alpha (TGFα), amphiregulin, and
heparin-binding EGF-like growth factor. EGFR ligands are produced by
proteolytic cleavage from the extracellular domains of cell surface pro-
teins or secreted precursor proteins. Most of the EGF family of growthCHX, cycloheximide; BS3,
ean; Sec, selenocysteine
.factors are biologically active only in their soluble secreted forms, but
some are also active as transmembrane precursor molecules [3]. Thus,
EGFR is involved in endocrine, paracrine, and autocrine signalingmech-
anisms responding to systemic, local tissue, and intercellular cues. The
EGFRnetwork regulates growth, proliferation, differentiation andmotil-
ity through pathways such as extracellular signal-regulated kinase
(ERK), phosphatidylinositol-3-kinase (PI3K), mitogen-activated protein
kinase (MAPK), and signal transducer and activator of transcription [4].
The EGFR network crosstalks extensively with other receptor tyrosine
kinases, G-protein coupled receptors, and cytokine receptors, and is a
major hub in the extracellular signaling network [5–8].
Ligand binding leads to asymmetric EGFR dimerization, induction of
the tyrosine kinase activity, auto-phosphorylation of the receptor, bind-
ing of cytoplasmic cofactors, internalization of the EGF-receptor com-
plex, and initiation of a complex network of signaling cascades.
Phosphorylated EGFR binds the E3 ubiquitin ligase Cbl, which adds
ubiquitin at several lysine residues [9]. The ubiquitinated receptor is
recognized by ubiquitin-binding domains in several members of the
endosomal sorting complex for retrograde transport (“ESCRT”) protein
complex. Ubiquitinated EGFR is endocytosed and trafﬁcked to
lysozomes for degradation, or alternatively, EGFR can be de-
ubiquitinated and recycled to the plasma membrane for re-use [10].
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EGFR degradation and recycling, and ultimately, the amount of EGFR
expressed on the cell's surface.
SelenoproteinW (SEPW1) is a 9 kDa thioredoxin-like protein with a
selenocysteine (Sec) residue at the active site. SEPW1 is ubiquitously
expressed and conserved in all major phyla except higher plants and
fungi. SEPW1 is cell cycle regulated, is required for cell cycle progres-
sion, and is the only selenoprotein whose mRNA was increased by
sub-micromolar concentrations of selenium in cultured human cells
[11]. We found that G1-phase cell cycle arrest from SEPW1 depletion
is mediated by phosphorylation of the p53 tumor suppressor protein
via p38 MAPK and JNK2 under control of MKK4 [12–14]. We report
here that SEPW1 is required for activation of EGFR upstream of
MKK4 for the EGF-stimulated proliferation of prostate and breast epi-
thelial cells. SEPW1 suppresses EGFR ubiquitination, which decreases
lysozomal degradation and increases surface EGFR concentration and
EGF responsiveness.2. Materials and methods
2.1. Cell culture
RWPE-1 and MCF-10A cells were obtained from the American Type
Culture Collection (“ATCC”, Manassas, VA) and maintained in serum-
free medium supplemented with EGF as described before [11].2.2. siRNA transfections
Cellswere transfected inmedium containing either 0 or 5 ng/mLEGF
per previously established protocols [14] with Silencer Select siRNAs
targeting SEPW1 (s361, s363) or non-targeting control siRNAs #1 and
#2 (ABI, Foster City, CA). Data identiﬁed as “SEPW1 siRNA” refers to
siRNA s361, unless indicated otherwise.2.3. SEPW1 overexpression vector transfections
Approximately 300,000 RWPE-1 cells per well were seeded in six
well dishes on the day prior to transfection. The cells in each well
were transiently transfected with either 2 μg SEPW1 TrueClone cDNA
clone in a p-CMV6-Neo vector or the empty vector (Origene, Rockville,
MD) with 10 μL Superfect Reagent (QIAGEN, Valencia, CA) per
manufacturer's instructions. Three hours after the addition of transfec-
tion complexes, the cells were rinsed and supplied with fresh medium.2.4. Cell cycle analysis
Propidium iodide staining of cellular DNA, ﬂow cytometry, and data
analysis were performed as described before [14].2.5. Western blots
Western blot analyses were conducted using antibodies targeting
the following proteins: EGFR (pan-speciﬁc), p-Tyr-992-EGFR, p-Tyr-
1045-EGFR, p-Tyr-1068 EGFR, ubiquitin (Cell Signaling Technologies,
Danvers, MA), β-actin, β-tubulin, and vinculin (Sigma). PVDF mem-
branes were stripped with Restore Plus reagent (Pierce, Rockford, IL),
and re-probed as needed. The immunoblots were imaged with a
ChemiDoc XRS+ system (BioRad, Hercules, CA), and densitometry
was performed with ImageLab software (BioRad). The chemilumines-
cence of each protein band was normalized to the average chemilumi-
nescence of all the bands of the same protein from the corresponding
immunoblot prior to combined statistical analysis from multiple blots.2.6. Proteome proﬁler human phospho-MAPK arrays
Two hundred μg total protein from each lysate was hybridized to
Proteome Proﬁler Human Phospho-MAPK antibody arrays (R&D Sys-
tems, Minneapolis, MN) per manufacturer's protocol, and all the arrays
were imaged simultaneously with the ChemiDoc XRS+ System. Densi-
tometry was conducted with ImageLab software, and all the densitom-
etry values were divided by 1000 for data presentation simpliﬁcation.
The average intensity of two negative control spots on each array was
subtracted from the protein kinase spot intensities of the corresponding
array for background correction.2.7. Chemical crosslinking of cell surface receptors
EGF-starved cells were treated with 100 ng/mL EGF for 30 min at
4 °C, placed on ice, washed three timeswith ice-cold PBS, and then incu-
bated with the non-membrane permeable crosslinking reagent
bis(sulfosuccinimidyl)suberate (BS3, Pierce), 3 mM, in PBS for 2 h at
4 °C. Excess BS3 was quenched by addition of 1 M Tris–HCl, pH 7.4 to
a ﬁnal concentration of 20 mM and holding at 4 °C for 15 min.
Cells were then washed with PBS, lysed, and the lysates analyzed by
immunoblotting.2.8. Fluorescent EGF internalization
Cells transfected and grown on coverslips were starved of EGF
overnight and then stimulated with medium containing 970 ng/mL
Alexa Fluor 488 streptavidin–biotin conjugated EGF (equivalent to
100 ng/mL EGF; Invitrogen), washed with PBS, ﬁxed in ice-cold
100% methanol for 4 min, counter-stained with 4′,6-diamidino-2-
phenylindole (DAPI, Sigma), and mounted on slides using SlowFade
reagent (Invitrogen). The images were acquired on an FV1000 laser
scanning confocal microscope (Olympus, Center Valley, PA). Total
background-corrected Alexa Fluor 488 intensity of each image was
measured with ImageJ software [43,44] and ﬂuorescent EGF signal per
cell was calculated by dividing the whole image signal intensity by the
total number of cells in the image.2.9. Measurement of surface receptor expression
Cell pellets were washed with ice-cold PBS containing 2 mM EDTA
and 1% FBS (blocking buffer), ﬁxed in PBS with 4% paraformaldehyde
for 20 min on ice, washed again, and counted. Approximately 200,000
cells per sample were incubated with 1:50 EGFR antibody Ab-3 (Ther-
mo Scientiﬁc) diluted in equal volumes of cold blocking buffer, washed,
and then stainedwith 1:200 Alexa Fluor 488 conjugated anti-mouse an-
tibody (Cell Signaling Technology). At least 40,000 events per sample
were collected on a FACSCanto ﬂow cytometer (BD Biosciences), and
FITC area peak mean intensities were calculated by FACSDiva software
(BD Biosciences).2.10. Receptor immunoprecipitation
Cells were lysed with M-Per buffer containing HALT protease and
phosphatase inhibitor cocktails (Pierce), and 400 μg total protein from
each lysate were incubated with 1:100 EGFR antibody D38B1 (Cell Sig-
naling Technology) in equal buffer volume for 1 h at 4 °C on a rocker.
50 μL Protein A/G Agarose Plus beads (Santa Cruz Biotechnology)
were added to each sample prior to overnight incubation at 4 °C with
rocking. The beads were washed ﬁve times with PBS and then boiled
in reducing sample loading buffer for 5 min, and the supernatants
were analyzed by immunoblotting.
Table 2
SEPW1 silencing decreases EGF-stimulated S-phase entry in MCF-10A breast epithelial
cells.
siRNA treatment [EGF],
ng/mL
Percentage of cells (±SEM)
G0 and G1 S-phase G2 and M
No transfection 0 85.6 ± 0.0 9.4 ± 0.1 5.0 ± 0.1
5 72.2 ± 0.9 18.2 ± 0.6 9.6 ± 0.2
Non-targeting control siRNA 0 89.1 ± 0.1a 6.7 ± 0.3a 4.2 ± 0.2a
5 77.5 ± 0.0b 14.6 ± 0.1b 7.8 ± 0.1b
SEPW1 siRNA 0 91.5 ± 0.2c 5.0 ± 0.0c 3.5 ± 0.1a
5 83.6 ± 0.5d 9.4 ± 0.2d 6.9 ± 0.3d
Three days after transfection, cells were ﬁxed, stained with propidium iodide, and their
DNA contentsmeasured by ﬂow cytometry. Cell cycle phase distributions were calculated
with ModFit LT 3.0. Analyses were performed in duplicate and the data shown are the
means ± SE. SEPW1 siRNA-treated cells were compared to the control cells with a two-
way ANOVA and Tukey's multiple comparisons test. Means within a column not sharing
a superscript are signiﬁcantly different (p b 0.05). Representative pseudo-color density
plots of events and cellular DNA content are shown in Supplemental Figure S2.
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RWPE-1 cells were transfected with 0.2% siPORT Amine reagent
(ABI) and 30 nM of one of three Silencer SEPW1 siRNAs (#42029,
41942, or 41846), or with 30 nM non-targeting control siRNA AM4635
(ABI). RNA was isolated and analyzed with whole genome DNA micro-
arrays (Affymetrix HG-U133 Plus 2.0) as described previously [14].
There were 664 genes differentially expressed (p b 0.002) in SEPW1-
depleted cells.
2.12. Statistical analysis
Each experiment was performed at least twice, and two biological
replicates per condition were analyzed in each experiment, except for
immunoblots. In the case of Western blot analyses, every independent
experiment contained one biological replicate. No technical replicates
were run. Data from different treatments were compared using two-
way analysis of variance (ANOVA) or t-tests with SigmaPlot 12.3 soft-
ware (Systat). Estimates of experimental variability are expressed as
standard error of themean (SE). Between-group comparisons were an-
alyzed with Tukey's test. A probability of ≤0.05 was considered
signiﬁcant.
3. Results
3.1. SEPW1 depletion blocks EGF-stimulated cell cycle entry
Because G1 arrest from SEPW1 depletion was ﬁrst observed in cells
that only proliferate in the presence of added EGF, we speculated
that SEPW1 might be required for EGF-stimulated cell cycle entry.
When grown continuously in 5 ng/mL EGF, 31.4% of RWPE-1 cells
were in S-phase versus 5.1% without EGF, indicating 26.3% entered the
cell cycle in response to EGF (Table 1). In contrast, only 8.2% of
SEPW1-depleted RWPE-1 cells entered the cell cycle in response to
EGF; less than one-third the rate in control cells. We observed a similar
response in breast cells: When grown continuously in 5 ng/mL EGF,
14.6% of MCF-10A cells were in S-phase versus 6.7% without EGF, indi-
cating 7.9% entered the cell cycle in response to EGF (Table 2). However,
only 4.4% of SEPW1-depletedMCF-10A cells entered the cell cycle in re-
sponse to EGF; about half the rate in control cells. Accordingly, we con-
clude that SEPW1 is required for EGF-stimulated cell cycle entry in both
prostate and breast epithelial cells.
3.2. SEPW1 depletion decreases EGFR auto-phosphorylation and total EGFR
EGF binding stimulates auto-phosphorylation of several Tyr residues
in the cytoplasmic domain of EGFR. Phosphorylation of Tyr-992, Tyr-Table 1
SEPW1 silencing decreases EGF-stimulated S-phase entry in RWPE-1 prostate epithelial
cells.
siRNA treatment [EGF],
ng/mL
Percentage of cells (±SEM)
G0 and G1 S-phase G2 and M
No transfection 0 83.1 ± 0.2 9.8 ± 0.2 7.1 ± 0.1
5 60.6 ± 1.9 32.7 ± 1.2 6.6 ± 0.8
Non-targeting control siRNA 0 86.1 ± 0.9a 5.1 ± 0.3a 8.8 ± 1.2a
5 61.7 ± 0.3b 31.4 ± 0.1b 6.9 ± 0.2a,c
SEPW1 siRNA 0 82.4 ± 3.3a 11.1 ± 3.6c 6.4 ± 0.3b
5 74.8 ± 1.6c 19.3 ± 0.2d 5.9 ± 1.4b,c
Three days after transfection, cells were ﬁxed, stained with propidium iodide, and their
DNA contentsmeasured by ﬂow cytometry. Cell cycle phase distributions were calculated
withModFit LT 3.0 software. The experimentwas conducted twice and two biological rep-
licates were analyzed in each experiment. The data shown are the means ± SE. SEPW1
siRNA-treated cells were compared to the control cells with a two-way ANOVA and
Tukey's multiple comparisons test. Means within a column not sharing a superscript are
signiﬁcantly different (p b 0.05). Representative pseudo-color density plots of events
and cellular DNA content are shown in Supplemental Figure S1.1045, and Tyr-1068 is associated with downstream signaling events
[21,45]. Control and SEPW1-depleted RWPE-1 cells were starved of
EGF overnight, re-supplied with 100 ng/mL EGF, and then analyzed
with Western blots for total EGFR, p-Tyr-992-EGFR, p-Tyr-1045-EGFR,
and p-Tyr-1068-EGFR. SEPW1 silencing decreased EGF-induced phos-
phorylation of the receptor on all three Tyr residues investigated and
decreased total EGFR (Fig. 1). Because lower phospho-EGFR couldmere-
ly reﬂect the amount of total EGFR, we also examined the ratio of
phospho-EGFR/total EGFR. At 5 min, when EGFR phosphorylation was
maximal, SEPW1 depletion decreased the ratio of phospho-EGFR/total
EGFR for p-Tyr-992-EGFR, p-Tyr-1045-EGFR, and p-Tyr-1068-EGFR by
43%, 79%, and 63%, respectively, indicating EGFR auto-phosphorylation
wasdecreased to a greater degree than total EGFR. This probably reﬂects
the fact that auto-phosphorylation requires two EGFR monomers to
form a dimer, and, is thus a second-order process with respect to
EGFR concentration. Therefore, a relatively small change in total EGFR
causes a much larger change in the rate of auto-phosphorylation. To
guard against off-target effects, we repeated these experiments with a
second siRNA targeted to a different sequence in SEPW1 (s363). EGFR
phosphorylation at all three sites was decreased by SEPW1 siRNA
s363 (Supplemental Figure S4), conﬁrming this effect is speciﬁc to
SEPW1 depletion.
3.3. SEPW1 overexpression enhances EGFR auto-phosphorylation
To ensure the effects of SEPW1 siRNA on EGFR auto-phosphorylation
were not due to RNAi artifacts, we checked whether transient overex-
pression of SEPW1 would have the opposite effect. Overexpressing
wild-type SEPW1 containing the N-terminal selenocysteine residue in-
creased SEPW1 protein by approximately three-fold in RWPE-1 cells
(Fig. 2). Cells transfected with the SEPW1 overexpression vector
or empty vector were starved of EGF overnight, and then stimulated
with 100 ng/mL EGF. Five minutes after EGF addition, EGFR auto-
phosphorylation on Tyr 1068 and Tyr 1045 was 2.7- and 1.8-fold great-
er, respectively, in SEPW1-overexpressing cells compared to empty
vector-transfected control cells and remained higher throughout the
time course. However, total EGFR levelswere not signiﬁcantly increased
by SEPW1 overexpression. The fact that SEPW1 overexpression had an
opposite effect on EGFR auto-phosphorylation from SEPW1 depletion
indicates the effect of siRNA on EGFR auto-phosphorylation was specif-
ically due to altered expression of SEPW1 and was not an artifact of
RNAi technology.
3.4. SEPW1 depletion blocks EGF-stimulated activation of downstream pro-
tein kinases
EGF binding to EGFR activates several signaling pathways. To assess
the effect of SEPW1 depletion on pathways downstream from the EGFR,
Fig. 1. SEPW1 depletion inhibits auto-phosphorylation of the EGF receptor. Two days after transfection with SEPW1 siRNA (open circles) or non-targeting control siRNA (solid circles),
RWPE-1 cells were starved in EGF-free medium overnight, and then stimulated with medium containing 100 ng/mL EGF. Cells were lysed at 0, 5, 15, 30, 45 and 60 min post-EGF stimu-
lation and the lysates were analyzed with Western blots using the indicated phospho-speciﬁc and pan-speciﬁc antibodies for EGFR. β-Tubulin served as a loading control. Because total
EGFR also decreased with SEPW1 depletion, the data are displayed as ratios of phospho-EGFR/total EGFR. A representative immunoblot from a single experiment (lower panel; cnt,
non-targeting control siRNA;W, SEPW1 siRNA) and the averages ± SE from three independent experiments conducted with two SEPW1 siRNAs and two control siRNAs (upper panel)
are shown. Asterisks indicate the time points at which EGFR phosphorylation was signiﬁcantly different between the control siRNA and SEPW1 siRNA (p b 0.05, two-way ANOVA with
Tukey's test). Results from individual SEPW1 and control siRNAs are shown in Supplemental Figures S3 and S4.
Fig. 2. SEPW1 overexpression enhances auto-phosphorylation of the EGF receptor. One day after transfectionwith a SEPW1 overexpression construct (open circles) or empty vector (solid
circles), RWPE-1 cells were starved in EGF-free medium overnight, and then stimulated with medium containing 100 ng/mL EGF. Cells were lysed at 0, 5, 15, 30, 45 and 60 min post-EGF
stimulation and the lysates were analyzedwithWestern blots using the indicated phospho-speciﬁc and pan-speciﬁc antibodies for EGFR. β-Actin served as a loading control. The data are
displayed as ratios of phospho-EGFR/total EGFR. A representative immunoblot from a single experiment (lower panel; Vec, empty vector; W-OE, SEPW1 overexpression vector) and the
averages ± SE from three independent experiments (upper panel) are shown. Asterisks indicate the time points at which EGFR phosphorylation was signiﬁcantly different between the
vector control and SEPW1 overexpression (p b 0.05, two-way ANOVA with Tukey's test).
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Table 3
SEPW1 depletion attenuates EGF-stimulated activation of downstream protein kinases.
Activated kinase Control siRNAs SEPW1 siRNAs
Pan Ser(P)-Akt 1400 ± 311 667 ± 67
Ser(P)-133-CREB 613 ± 83 274 ± 64
Thr(P)-202/Tyr(P)-204-ERK1 1364 ± 117 562 ± 290
Thr(P)-185/Tyr(P)-187-ERK2 3233 ± 255 978 ± 607
Ser(P)-21/Ser(P)-9-GSK3-α/β 1006 ± 117 479 ± 109
Ser(P)-9-GSK-3β 1509 ± 459 547 ± 369
Ser(P)-360-MSK2 643 ± 22 229 ± 40
Thr(P)-180/Tyr(P)-182-p38α 646 ± 31 253 ± 31
Ser(P)-380-RSK1 941 ± 2 415 ± 87
Two days after transfection with two non-targeting siRNAs (Control #1 and Control #2),
or two different siRNAs for SEPW1 (s361 and s363), cells were starved of EGF overnight,
and then stimulated with 100 ng/mL EGF for 1 h. The cells were lysed, and lysates were
hybridized to Proteome Proﬁler Human Phospho-MAPK antibody arrays. Phosphorylation
of nine kinases listed in the table above was signiﬁcantly decreased due to SEPW1 deple-
tionwith either siRNA (p b 0.05, two-wayANOVA and Tukey'smultiple comparisons test).
The data shown are array spot densitometry averages from the two controls or SEPW1
siRNAs ± SE. Densitometry values for all the protein kinases from each individual siRNA
are listed in Supplemental Table S1, and the image of the arrays is displayed in Supplemental
Figure S5.
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the activating phosphorylations on 26 protein kinases in starved cells
stimulated with EGF for 60 min. EGF treatment of cells transfected
with two different non-targeting control siRNAs induced phosphoryla-
tion of most of the kinases on the array (Supplemental Figure S5). Trans-
fection of cells with either of two siRNAs targeting different sequences
in the SEPW1 mRNA signiﬁcantly suppressed EGF-stimulated phos-
phorylation of nine out of 26 kinases on the array (Table 3), conﬁrming
that SEPW1depletion inhibits transmission of the EGF signal tomultiple
downstream pathways.3.5. SEPW1 depletion decreases EGF-induced EGFR dimers
EGFR tyrosine kinase is fully active onlywhen dimerized, eitherwith
anothermolecule of EGFR or with another receptor tyrosine kinase. EGF
binding stabilizes and reconﬁgures EGFR dimers, thus activating the ty-
rosine kinase activity and initiating intracellular signaling [15]. When
EGF-starved RWPE-1 cells were treated with the membrane-
impermeable crosslinking reagent BS3 without the addition of EGF,
EGFR-immunoreactive high molecular weight signals could not
be detected in control or SEPW1-silenced cells (left lanes in Fig. 3).
EGF treatment induced a prominent EGFR-immunoreactive band at
the dimer molecular weight of approximately 340 kDa in control cells
that was greatly diminished (by 84 ± 14%) in SEPW1-depleted cells
(Fig. 3).Fig. 3. SEPW1 depletion inhibits formation of EGFR dimers. Two days after transfectionwith SEP
overnight, incubated with cold medium containing 100 ng/mL EGF for 30 min at 4 °C, and trea
analyzed with Western blots using pan-speciﬁc antibodies for EGFR. Quantitative densitometr
EGFR dimers at (approximately) 340 kDa. The percentage of dimers formedwith each siRNA tr
was conducted twice. A representative immunoblot from a single experiment is shown.3.6. SEPW1 depletion inhibits EGF-induced EGFR endocytosis
EGFR is rapidly internalized by endocytosis after EGF binding [16].
We treated EGF-starved RWPE-1 cells with ﬂuorescently-labeled EGF
and examined themby confocalmicroscopy. Fiveminutes after addition
of labeled EGF, SEPW1-depleted cells contained only about 40% asmuch
ﬂuorescent EGF per cell (Fig. 4A), indicating that EGFR endocytosis was
suppressed in SEPW1-depleted cells.
3.7. SEPW1 depletion decreases surface expression of EGFR
Although EGFR at the plasma membrane can be imaged with a con-
focal microscope, the resolution is not adequate to differentiate EGFR
actually on the extracellular surface from receptor in vesicles closely as-
sociated with the membrane. We used a monoclonal antibody speciﬁc
for an epitope on the receptor's extracellular domain to label surface
EGFR in continuously growing RWPE-1 cells and then measured the
amount of surface EGFR per cell by ﬂow cytometry. We tracked EGFR
membrane expression prior to siRNA transfection, and on three consec-
utive days after transfection (Fig. 4B). Two days after transfection, the
average amount of surface EGFR on SEPW1-depleted cells dropped to
54% of the level on control cells, and extracellular EGFR remained signif-
icantly low in SEPW1-silenced cells on the third day.
3.8. SEPW1 depletion accelerates EGFR degradation
Internalized EGFR is trafﬁcked through endosomes, some portion
is recycled, and then eventually the receptor is sorted to lysozomes
for degradation. When protein synthesis is inhibited, the rate of disap-
pearance of EGFR from cells is an indication of the receptor's rate of
degradation. We treated continuously growing RWPE-1 cells with cy-
cloheximide to inhibit synthesis of new protein and measured total
EGFR protein for 6 h (Fig. 5). In control cells, EGFRdecreasedwith an ap-
parent ﬁrst-order half-life of 9.4 ± 1.5 h, whereas the apparent half-life
was decreased to 3.3± 0.2 h in SEPW1-depleted cells (p= 0.02; n= 3,
two-tailed, two sample equal variance t-test). Thus, the rate of EGFR
degradation was increased approximately three-fold in SEPW1-
depleted cells.
3.9. SEPW1 depletion increases EGFR ubiquitination
EGFR endocytosis stimulated by high-dose EGF is tightly coupled to
ubiquitination of the receptor [17]. After internalization, subsequent
trafﬁcking of EGFR is determined largely by its ubiquitination
state [10], which is dynamically regulated through the action of ubiqui-
tin ligase and de-ubiquitinase enzymes [18]. Western blots of
immunoprecipitated EGFR showed the receptor lacked detectableW1 siRNA or non-targeting control siRNA, RWPE-1 cells were starved in EGF-freemedium
ted with 3 mM BS3 for 2 h at 4 °C as detailed under Materials and methods. Lysates were
y was conducted to estimate the chemiluminescence of EGFR monomers at 170 kDa and
eatment was calculated from the total of monomer and dimer intensities. The experiment
Fig. 4. EGFR endocytosis and surface EGFR expression are decreased by SEPW1 depletion. A—Two days after transfectionwith SEPW1 siRNA or a non-targeting control siRNA, RWPE-1 cells
grown on coverslips were starved in EGF-free medium overnight, and stimulated with basal medium containing 970 ng/mL Alexa Fluor 488-labeled EGF for 5 min. The coverslips were
processed, imaged, and EGF signal per cell was calculated as described under Materials and methods. At least 100 cells per siRNA treatment were analyzed in each experiment from du-
plicate slides, and the experiment was conducted three times. The asterisk indicates SEPW1-silenced cells had signiﬁcantly less endocytosed EGF compared to controls 5 min after ﬂuo-
rescent EGF addition (p b 0.001, two-way ANOVA with Tukey's test). Alexa Fluor 488-EGF is displayed as green and nuclei as blue. B—RWPE-1 cells grown continuously in medium
supplemented with 5 ng/mL EGF were harvested and ﬁxed before siRNA transfection (Pre-TF), and on Days 1, 2, and 3 post-transfection (Days Post-TF). The cells were then stained,
and analyzed for cell surface EGFR by ﬂow cytometry. The experiment was conducted twice, and the samples were run in duplicate. Representative histograms of SEPW1-silenced cells
(yellow) and control cells (red) two days after transfection are shown. The asterisks indicate SEPW1-depleted cells had signiﬁcantly lower surface EGFR expression on Days 2, and 3
post-transfection (p b 0.02, two-way ANOVA with Tukey's test).
Fig. 5. SEPW1 depletion increases EGFR turnover rate. Three days after transfection with
SEPW1 siRNA (open circles) or non-targeting control siRNA (solid circles), RWPE-1 cells
were incubated with medium containing 60 mg/mL cycloheximide (CHX) to inhibit
protein synthesis. Lysates were collected before (0 h) and at 0.5 h, 1 h, 2 h, 4 h and 6 h
after CHX addition, and analyzed with Western blots using pan-speciﬁc EGFR antibodies.
β-Tubulin served as a loading control. The experiment was repeated three times. A repre-
sentative immunoblot from a single experiment and the regression of log EGFR chemilu-
minescence versus time from the corresponding blot is shown (cnt, non-targeting
control siRNA;W, SEPW1 siRNA).
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after EGF stimulation (Fig. 6). Two minutes after adding EGF, the EGFR
in SEPW1-depleted cells was modiﬁed with three times as much ubiq-
uitin as in control cells, indicating that SEPW1 depletion increases
ubiquitination of EGFR. In order to guard against off-target RNAi
effects, we conﬁrmed these results with a second siRNA targeted to a
different sequence in SEPW1 mRNA (s363). EGFR ubiquitination
was increased by SEPW1 siRNA s363 similarly to siRNA s361
(Supplementary Figure S6). These results suggest SEPW1 either inhibits
the process of ubiquitination or enhances removal of ubiquitin from
the receptor.3.10. SEPW1 depletion alters expression of genes in the EGFR pathway
We used whole genome DNA microarrays to assess the effect of
SEPW1 depletion on gene expression in RWPE-1 cells. EGFR itself and
IGF1R, which cross-activates EGFR, were up-regulated (Table 4). Also
up-regulated were two EGFR ligands – TGFα and EGF – containing
ﬁbulin-like extracellular matrix protein 1, alongwith vascular endothe-
lial growth factor A and transforming growth factor beta 1, whose
receptors both transactivate the EGFR [19,20]. Two genes required
for receptor endocytosis – RAB5A and EEA1 – were also up-regulated
in SEPW1-depleted cells. Thus, the EGF receptor itself, an EGFR-
transactivating receptor, two EGFR ligands, two EGFR-transactivating li-
gands, and two EGFR trafﬁcking factors were up-regulated in SEPW1-
depleted cells, suggesting a compensatory response to the blockade in
EGF signaling caused by SEPW1 depletion.
Fig. 6. EGFR ubiquitination is increased by SEPW1 depletion. Two days post-transfection
with SEPW1 siRNA s361 or a non-targeting control siRNA, RWPE-1 cells were starved
overnight, incubatedwithmedium containing 0 or 100 ng/mL EGF for 2min, and then im-
mediately lysed. EGFR was immunoprecipitated from the lysates and the immunoprecip-
itates were analyzed for ubiquitin and EGFR by immunoblotting. The experiment was
repeated four times. Arrowheads indicate the approximate position of ubiquitinated
EGFR. SEPW1-silenced cells had signiﬁcantly more ubiquitinated EGFR (p = 0.037; two-
way ANOVA with Tukey's test).
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We have presented evidence that SEPW1 is involved in EGFR signal-
ing. Silencing SEPW1 inhibited EGF-stimulated cell cycle entry in breast
and prostate epithelial cells. In addition, SEPW1 depletion inhibited di-
merization, auto-phosphorylation and endocytosis of EGFR, decreased
total and surface EGFR, and attenuated EGF-stimulated activation of
downstreamprotein kinases, but increased ubiquitination and degrada-
tion of EGFR. Importantly, overexpressing SEPW1 had an opposite effect
and increased EGFR phosphorylation. These results suggest SEPW1 reg-
ulates EGFR ubiquitination, which controls endosomal trafﬁcking and
recycling of the receptor, thus determining surface EGFR expression
and the cell's responsiveness to EGF.
In the currentmodel of EGFR activation, auto-phosphorylation of the
receptor cytoplasmic domain causes binding of Cbl ubiquitin ligase and
other proteins, receptor ubiquitination, and receptor internalization
[21]. Once internalized the receptor may continue signaling, or be
recycled to the cell surface, or be sorted to lysozomes for degradation.
Consequently, trafﬁcking of the receptor through endosomes controls
a cell's sensitivity to EGF and enables the spatial and temporalTable 4
SEPW1 depletion alters expression of genes in the EGFR pathway.
Symbol Gene name mRNA
(% of control)
SEPW1 Selenoprotein W, 1 43%
EFEMP1 EGF-containing ﬁbulin-like extracellular
matrix protein 1
270%
IGF1R Insulin-like growth factor 1 receptor 191%
TGFB1 Transforming growth factor, beta 1 178%
TGFA Transforming growth factor, alpha 164%
EGFR Epidermal growth factor receptor 145%
VEGFA Vascular endothelial growth factor A 145%
RAB5A Member RAS oncogene family 164%
EEA1 Early endosome antigen 1 155%
RWPE-1 cells were transfected separatelywith three siRNAs targeting different sequences
in SEPW1 mRNA, or a non-targeting control siRNA. RNA was extracted and labeled for
analysis on Affymetrix GeneChips as described under Materials and methods. Genes
shownwere called signiﬁcantly changed by GCOS (p b 0.002) for all three SEPW1 siRNAs
compared to the control siRNA.Microarray data from individual siRNAs are shown in Sup-
plemental Table S2.regulation of EGFR signaling [22]. After internalization, ubiquitinated
EGFR is sorted to late endosomes and thence to lysozomes for degrada-
tion, whereas de-ubiquitinated EGFR is sorted to recycling endosomes,
stripped of ligand and then returned to the plasma membrane for re-
use.
Our results indicate SEPW1 antagonizes EGFR ubiquitination, either
by inhibiting ubiquitination, or by enhancing de-ubiquitination. The to-
tality of the evidence suggests SEPW1 most likely enhances de-
ubiquitination. Silencing SEPW1 decreased every aspect of EGFR activa-
tion we measured except EGFR ubiquitination and EGFR degradation,
tightly linked processes that were both up-regulated in SEPW1-
depleted cells. EGFR endocytosis initiated by high dose EGF is preceded
by, and is dependent on, ubiquitination of the receptor [23]. The fact
that SEPW1 silencing decreased EGFR endocytosis and increased EGFR
ubiquitination at the same time suggests that SEPW1 enhances de-
ubiquitination of endosomal EGFR after endocytosis, rather than
inhibiting EGFR ubiquitination before or during endocytosis.
The native biochemical activity andmolecular function of SEPW1 re-
main obscure. The best characterized molecular interactions of SEPW1
are with 14-3-3 proteins, a family of phosphoprotein-binding proteins
with diverse regulatory functions in the cell. 14-3-3 proteins have mul-
tiple functions in EGFR signaling: 14-3-3ζ interacts directlywith EGFR in
ﬁbroblasts [24] and inhibits Raf — the MAP3K target of EGFR-activated
Ras [25]; dominant-negative 14-3-3ζ blocks EGFR-mediated ERK
activation by serum [26]; and, 14-3-3γ regulates both the MAPK and
the PI3K/Akt pathways [27] downstream of EGFR. SEPW1 binds to 14-
3-3 proteins [28] and is hypothesized to control their function by
reacting with, or regulating the oxidation state of, an exposed Cys resi-
due [29]. Alterations of 14-3-3 redox state and/or conformation by
SEPW1have been invoked to explain howSEPW1knockdown enhances
binding of 14-3-3 to CDC25B [30] and mTORC [31], which inhibits the
activities of both targets. It is tempting to speculate that 14-3-3 may
have a similar role in this pathway.
Ubiquitin-speciﬁc protease 8 (USP8) is one of two deubiquitinases
that remove ubiquitin from endosomal EGFR [32]. EGFR activation
causes USP8 to become phosphorylated and to associate with EGFR on
endosomes where it dynamically regulates EGFR ubiquitination state
during trafﬁcking. Depletion of USP8 with siRNA inhibits EGFR activa-
tion and increases EGFR degradation [32], similar to the effect of deplet-
ing SEPW1, and suggests the possibility SEPW1 might regulate USP8.
14-3-3 binds to USP8 in a phosphorylation-dependent manner and in-
hibits its catalytic activity [33]. If SEPW1 acts as proposed for CDC25B
and mTORC, then SEPW1 could cause 14-3-3 to dissociate from USP8,
relieving the inhibition and increasing de-ubiquitination of EGFR. Such
a mechanism would be consistent with the observed increase in EGFR
ubiquitination when SEPW1 is silenced.
When EGF and many other growth factors bind to their receptors,
H2O2 is produced due to the actions of NADPH oxidase and
superoxide dismutase [34,35]. SEPW1 has glutathione-dependent
H2O2-catabolizing antioxidant activity in vitro [36], but its in vivo role
as an antioxidant has been questioned [37]. Indeed, chemical antioxi-
dants and the antioxidant selenoproteins GPX1 andGPX4 have opposite
effects on EGF signaling from SEPW1. Small molecule antioxidants in-
hibit EGFR auto-phosphorylation [34] and dimerization [38], while
overexpression of the antioxidant selenoproteins GPX1 or GPX4 blocks
EGF-stimulated S-phase entry [39,40] rather than enhancing EGFR acti-
vation like over-expression of SEPW1. To the extent that SEPW1 regu-
lates oxidation-reduction, it appears to act more as a pro-oxidant than
as an antioxidant in this system.
EGF is an important promoter of cell cycle progression. Drugs that
block EGF binding or inhibit EGFR tyrosine kinase activity cause G1 ar-
rest and apoptosis in cancer cells. We observed a profound G1 arrest
after withdrawal of EGF (Tables 1 and 2), but we did not observe signif-
icant numbers of cells with a sub-G0/G1 DNA content that would indi-
cate apoptosis, perhaps because RWPE-1 cells are normal, non-
cancerous prostate cells (Figures S1 and S2, Supplemental Materials).
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breast and prostate epithelial cells, the cells that give rise to most tu-
mors in these tissues. This is consistent with recent reports that
SEPW1 is over-expressed in tumors [41] and that knockdown of SelW
(the mouse homologue of SEPW1) increases sensitivity to anti-cancer
drugs [30]. In a previous study, mice fed a selenium-deﬁcient diet had
greatly reduced expression of SelW and increased expression of the
EGFR ligand Creld1 [42], suggesting dietary selenium regulates EGFR
signaling in-vivo. The ubiquitous expression and evolutionary conserva-
tion of SEPW1 suggest it may have an ancient and essential function.
Knowledge of the molecular function of SEPW1 and the mechanisms
by which it modulates EGFR ubiquitination should improve our under-
standing of the complex relationship between selenium intake and can-
cer risk.
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